DAILY CONCURRENT CHEMORADIOTHERAPY USING SUPERSELECTIVE INTRA-ARTERIAL INFUSION VIA SUPERFICIAL TEMPORAL ARTERY-PREOPERATIVE THERAPY FOR STAGE III, IV ORAL CANCER-

DOI 11 Citations 11 References
  • TOHNAI Iwai
    Department of Cell Therapy, Nagoya University School of Medicine
  • MITSUDO Kenji
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
  • NISHIGUCHI Hiroaki
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
  • FUKUI Takafumi
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
  • YAMAMOTO Noriyuki
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
  • UEDA Minoru
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
  • FUWA Nobukazu
    Department of Radiation Oncology, Aichi Cancer Center

Bibliographic Information

Other Title
  • 浅側頭動脈よりの超選択的動注化学療法と放射線療法の連日同時併用療法―Ｓｔａｇｅ　ＩＩＩ，ＩＶ口腔癌に対する術前治療―
  • —PREOPERATIVE THERAPY FOR STAGE III, IV ORAL CANCER—
  • ―Stage III，IV口腔癌に対する術前治療―

Abstract

Recently, daily concurrent chemoradiotherapy using new superselective intra-arterial infusion via superficial temporal arterial artery is attracting attention. The catheter with curved tip is inserted superselectively to the feeding artery of the tumor via the superficial temporal artery, allowing long-term catheterization. Forty-one patients with stage III, IV oral cancer were treated. Radiotherapy (total dose: 40Gy/4weeks) and superselective intra-arterial infusion chemotherapy using docetaxel (total dose: 60mg/m2, 15mg/m2/week) and cisplatin (total dose: 100mg/m2, 5mg/m2/day) were concurrently performed daily, followed by surgery. In 35 patients, intra-arterial infusion was successful (success rate: 85.4%) and no major complication was observed. The clinical effects were CR in 29 patients (82.9%), and pathological effects of resected tumor after surgery were pathological CR in 31 (88.6%). This method promises to be a new strategy of choice for the treatment of oral cancer.

Journal

  • Toukeibu Gan

    Toukeibu Gan 31 (3), 413-418, 2005

    Japan Society for Head and Neck Cancer

Citations (11)*help

See more

References(11)*help

See more

Keywords

Details 詳細情報について

  • CRID
    1390282680200118528
  • NII Article ID
    130004509875
  • DOI
    10.5981/jjhnc.31.413
  • ISSN
    18818382
    13495747
    http://id.crossref.org/issn/13495747
  • Text Lang
    ja
  • Data Source
    • JaLC
    • Crossref
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top